Denmark · Delayed Price · Currency is DKK TCM Group Earnings Call Transcripts
Fiscal Year 2026
-
Q2 revenue grew 7.4% year-over-year, with strong gains in Norway and stable gross margin. Order intake surged late in the quarter due to price increases, but market conditions remain challenging. Full-year guidance is maintained, with margin improvement expected in H2.
-
Q1 2026 saw 17.6% revenue growth, margin improvements, and strong B2C performance, with guidance maintained despite volatile order intake and input cost inflation. Retail segment expanded via acquisitions, and cash flow improved significantly.
Fiscal Year 2025
-
Q4 2025 saw 10.5% revenue growth and improved gross margin, driven by acquisitions and efficiency gains. 2026 guidance anticipates further revenue and profit growth, with full integration of Celebert and continued market recovery expected.
-
Q3 2025 saw 4.1% revenue growth and improved gross margin, driven by both B2B and B2C segments, with Denmark and Norway contributing. Full ownership of Celebat was acquired, and guidance for 2025 was narrowed. SG&A costs rose due to store acquisitions, but turnaround efforts are ongoing.
-
Q2 2025 saw 5% revenue growth and a 20% rise in adjusted EBIT, with improved gross margin and strong cash flow. Guidance for 2025 was narrowed due to muted consumer activity in late Q2, while the acquisition of Celebert and investments in digitalization support future growth.
-
Q1 2025 saw 5% revenue growth driven by strong B2C sales and recovery in Norway, while B2B order intake improved but with limited visibility for the second half. Gross margin and EBIT margin rose slightly, but free cash flow turned negative due to higher CapEx and tax timing.
Fiscal Year 2024
-
Q4 saw a 2% sales decline due to weak B2B, but B2C grew over 5% and order intake was strong. Gross margin and EBIT improved, with full-year results at the top end of guidance. 2025 outlook is cautiously optimistic, with margin pressure from costs and low B2B visibility.
-
Q3 saw 7% organic sales growth, led by strong B2C performance, while B2B/project sales declined. Gross margin and EBIT improved year-over-year, and full-year guidance was narrowed, with a positive outlook for B2C and continued B2B weakness.
-
Q2 delivered 30% revenue growth and strong B2C momentum, offsetting B2B weakness. Guidance was raised, with full-year revenue expected at DKK 1.125–1.2 billion and adjusted EBIT at DKK 0–90 million, supported by Aubo integration and improved margins.